High‐dose cutaneous exposure to mite allergen induces IgG‐mediated protection against anaphylaxis. Issue 7 (3rd May 2016)

• Record Type: Journal Article
• Authors: Hirai, T.; Yoshioka, Y.; Takahashi, H.; Handa, T.; Izumi, N.; Mori, T.; Uemura, E.; Nishijima, N.; Sagami, K.; Yamaguchi, M.; Eto, S.; Nagano, K.; Kamada, H.; Tsunoda, S.; Ishii, K. J.; Higashisaka, K.; Tsutsumi, Y.
• Is Part Of: Clinical & experimental allergy. Volume 46:Issue 7(2016:Jul.)
• Page Start: 992
• Page End: 1003
• Publication Date: 2016-05-03
• Subjects: anaphylaxis -- blocking antibody -- dust mite -- skin -- IgE; Allergy -- Periodicals; Immunology -- Periodicals; 616.97
• DOI: 10.1111/cea.12722
• Languages: English
• ISSNs: 0954-7894

Abstract

Summary: Background: The relationship among natural allergen exposure, induction of blocking antibody and the occurrence of atopic allergy—particularly in the presence of IgE production—is debatable. Objective: To clarify the relationship between the dose of cutaneous exposure to dust mite allergen and susceptibility to the IgE‐mediated allergic response in relation to IgG production. Methods: NC/Nga mice were epicutaneously exposed to various doses of Dermatophagoides pteronyssinus allergen to induce atopic dermatitis–like skin lesions. We then evaluated the skin lesions, induction of mite‐specific immune responses, and susceptibility to anaphylaxis. Results: Dose‐dependent exacerbation of atopic dermatitis–like skin lesions and increases in mite‐specific IgG and IgE production were observed. However, mice exposed to relatively low doses of mite allergen showed hypersusceptibility to mite allergen–specific anaphylaxis. We also showed that adoptive transfer of total IgG from Dp‐sensitized mice rescued mice from the hypersusceptibility seen in those exposed to low doses of mite allergen. Conclusions and Clinical Relevance: High‐dose cutaneous exposure to dust mites induced effective blocking IgG production, even if accompanied by IgE production. Our data might support the concept that an increase in IgG titre, not a decrease in IgE titre, is a marker of clinical improvement in allergen‐specific immunotherapy.